Sandip Prasad, MD, MPhil, discusses ENVISION trial findings on mitomycin for intravesical solution and patient selection in clinical practice.
|Videos|September 12, 2021
Dr. Elliot on ROBUST III trial of Optilume drug-coated balloon for anterior urethral strictures
Author(s)Urology Times staff
Advertisement
In this video, Sean P. Elliott, MD, MS, FACS, discusses the abstract, “Interim results for the ROBUST III trial evaluating the Optilume drug-coated balloon for anterior urethral strictures,” which was presented during the 2021 American Urological Association annual meeting. Elliott is a professor, vice chair of urology, and director of reconstructive urology at the University of Minnesota, Minneapolis.
Advertisement
Related to this article
OpenFlo incorporates a design that modifies key mechanical features of conventional Foley catheters.
Study design discussions can help patients weigh personalized marketing claims, according to Jean Cunningham, PharmD, BCPS.
VIR-5500 is a PSMA-targeted PRO-XTEN dual-masked T-cell engager entering phase 3 development for prostate cancer.
Marie-Pier St-Laurent, MD, FRCSC, explains how NeoBLAST combines imaging, TURBT, and ctDNA to identify candidates for bladder-sparing surveillance.
Bladder symptoms during IVF often reflect hormonal and pelvic floor changes, not infection, according to Aleece Fosnight, MSPAS, PA-C.
A national survey found US hospitals expanded CAUTI prevention over 20 years, but use of key catheter-removal strategies remains variable.
Rezūm improved symptoms and quality of life at 1 year vs combination pharmacotherapy in sexually active men with BPO while preserving sexual function.
Advertisement
Advertisement